Exhibit 99.2O
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
THIRD QUARTER
Percent Percent Percent
Change Change Change
2003 2002 Total Operations Currency
Sales to customers
by segment of
business
Consumer
Domestic $984 910 8.1% 8.1 --
International 857 751 14.1 6.4 7.7
1,841 1,661 10.8 7.4 3.4
Pharmaceutical
Domestic 3,285 2,939 11.8 11.8 --
International 1,550 1,338 15.8 5.5 10.3
4,835 4,277 13.0 9.7 3.3
Med Device &
Diagnostics
Domestic 2,145 1,740 23.3 23.3 --
International 1,634 1,401 16.6 7.5 9.1
3,779 3,141 20.3 16.3 4.0
Domestic 6,414 5,589 14.8 14.8 --
International 4,041 3,490 15.8 6.5 9.3
Worldwide $10,455 9,079 15.2% 11.7 3.5
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
NINE MONTHS
Percent Percent Percent
Change Change Change
2003 2002 Total Operations Currency
Sales to customers
by segment of
business
Consumer
Domestic $2,915 2,717 7.3% 7.3 --
International 2,536 2,196 15.5 8.4 7.1
5,451 4,913 11.0 7.8 3.2
Pharmaceutical
Domestic 9,825 8,831 11.3 11.3 --
International 4,559 3,885 17.4 4.6 12.8
14,384 12,716 13.1 9.2 3.9
Med Device &
Diagnostics
Domestic 5,797 5,161 12.3 12.3 --
International 4,976 4,105 21.2 9.2 12.0
10,773 9,266 16.3 10.9 5.4
Domestic 18,537 16,709 10.9 10.9 --
International 12,071 10,186 18.5 7.3 11.2
Worldwide $30,608 26,895 13.8% 9.5 4.3
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
THIRD QUARTER
Percent Percent Percent
Change Change Change
2003 2002 Total Operations Currency
Sales to customers by
geographic area
Domestic $6,414 5,589 14.8% 14.8 --
Europe 2,241 1,901 17.9 4.8 13.1
Western Hemisphere 576 505 14.1 11.3 2.8
excluding U.S.
Asia-Pacific, Africa 1,224 1,084 12.9 7.4 5.5
International 4,041 3,490 15.8 6.5 9.3
Worldwide $10,455 9,079 15.2% 11.7 3.5
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
NINE MONTHS
Percent Percent Percent
Change Change Change
2003 2002 Total Operations Currency
Sales to customers by
geographic area
Domestic $18,537 16,709 10.9% 10.9 --
Europe 6,909 5,589 23.6 5.5 18.1
Western Hemisphere 1,603 1,506 6.4 12.3 (5.9)
excluding U.S.
Asia-Pacific, Africa 3,559 3,091 15.1 7.8 7.3
International 12,071 10,186 18.5 7.3 11.2
Worldwide $30,608 26,895 13.8% 9.5 4.3
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures)
THIRD QUARTER
2003 2002 Percent
2003 Percent 2002 Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 10,455 100.0 9,079 100.0 15.2
Cost of products 2,980 28.5 2,611 28.7 14.1
sold
Selling, marketing 3,428 32.8 3,006 33.1 14.0
and administrative
expenses
Research Expense 1,177 11.3 952 10.5 23.6
In-process research -- -- -- -- --
& development
Interest (income) 12 0.1 (12) (0.1)
expense, net
Other (income) (91) (0.9) 129 1.4
expense, net
Earnings before 2,949 28.2 2,393 26.4 23.2
provision for taxes
on income
Provision for taxes 877 8.4 668 7.4 31.3
on income
Net earnings 2,072 19.8 1,725 19.0 20.1
Net earnings per $0.69 $0.57 21.1
share (Diluted)
Average shares 3,008.3 3,026.7
outstanding
(Diluted)
Effective tax rate 29.7% 27.9%
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures)
NINE MONTHS
2003 2002 Percent
2003 Percent 2002 Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 30,608 100.0 26,895 100.0 13.8
Cost of products 8,668 28.3 7,650 28.4 13.3
sold
Selling, marketing 10,077 32.9 8,866 33.0 13.7
and administrative
expenses
Research expense 3,195 10.4 2,715 10.1 17.7
In-process research 918 3.0 189 0.7
and development
Interest (income) 19 0.1 (84) (0.3)
expense, net
Other (income) (203) (0.6) 117 0.4
expense, net
Earnings before 7,934 25.9 7,442 27.7 6.6
provision for taxes
on income
Provision for taxes 2,582 8.4 2,229 8.3 15.8
on income
Net earnings 5,352 17.5 5,213 19.4 2.7
Net earnings per $1.78 $1.70 4.7
share (Diluted)
Average shares 3,012.0 3,066.0
outstanding
(Diluted)
Effective tax rate 32.5% 30.0%
Earnings excluding
In-process Research
& Development:
Earnings before 8,852[1] 28.9 7,631[2] 28.4 16.0
provision for taxes
on income
Net earnings 6,267[1] 20.5 5,402[2] 20.1 16.0
Net earnings per $2.08[1] $1.76[2] 18.2
share (Diluted)
Effective tax rate 29.2% 29.2%
[1] The difference between earnings before provision for
taxes on income, net earnings and earnings per share
(diluted) as reported and earnings before provision for
taxes on income, net earnings and earnings per share
(diluted) excluding IPR&D is $918 million, $915 million and
$0.30 per share, respectively, which is in-process research
& development charges.
[2] The difference between earnings before provision for
taxes on income, net earnings and earnings per share
(diluted) as reported and earnings before provision for
taxes on income, net earnings and earnings per share
(diluted) excluding IPR&D is $189 million and $0.06 per
share, respectively, which is in-process research &
development charges.
# # #